Taclonex Suspension
NDC Package 50222-501-66
Package Information
Taclonex (calcipotriene and betamethasone dipropionate) suspension is taclonex® Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years and older. This formulation utilizes a suspension delivery system. Marketed by Leo Pharma Inc., this product is identified by NDC 50222-501 and is authorized under FDA application NDA022185.
Identification & Billing
- RxCUI: 833461 - betamethasone dipropionate 0.0643 % / calcipotriene 0.005 % Topical Suspension
- RxCUI: 833461 - betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension
- RxCUI: 833463 - Taclonex Scalp (calcipotriene 0.005 % / betamethasone dipropionate 0.064 % ) Topical Suspension
- RxCUI: 833463 - betamethasone dipropionate 0.643 MG/ML / calcipotriene 0.05 MG/ML Topical Suspension [Taclonex]
- RxCUI: 833463 - Taclonex Scalp (calcipotriene 0.005 % / betamethasone 0.05 % (betamethasone dipropionate 0.064 % ) ) Topical Suspension
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 50222 - Leo Pharma Inc.
- 50222-501 - Taclonex
- 50222-501-66 - 10 PACKAGE in 1 BOX / 2 BOTTLE in 1 PACKAGE / 60 g in 1 BOTTLE
- 50222-501 - Taclonex
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (50222-501). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 50222-501-66 identifies a specific commercial package of 10 package in 1 box / 2 bottle in 1 package / 60 g in 1 bottle of Taclonex, a human prescription drug labeled by Leo Pharma Inc.. This suspension is formulated for topical use and contains calcipotriene hydrate; betamethasone dipropionate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Leo Pharma Inc. on June 01, 2008. The current certification is valid through December 31, 2026.
How is this Leo Pharma Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 50222050166. Quantities are measured in per "gm or gram", products billed per gram are products measured by weight.. There are 1200 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.